SAB Biotherapeutics (SABSW) EBT (2021 - 2025)
Historic EBT for SAB Biotherapeutics (SABSW) over the last 5 years, with Q3 2025 value amounting to -$12.1 million.
- SAB Biotherapeutics' EBT fell 1659.63% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.6 million, marking a year-over-year increase of 657.27%. This contributed to the annual value of -$41.9 million for FY2024, which is 59.45% up from last year.
- According to the latest figures from Q3 2025, SAB Biotherapeutics' EBT is -$12.1 million, which was down 1659.63% from -$9.8 million recorded in Q2 2025.
- SAB Biotherapeutics' EBT's 5-year high stood at $1.4 million during Q1 2021, with a 5-year trough of -$22.9 million in Q4 2023.
- In the last 5 years, SAB Biotherapeutics' EBT had a median value of -$7.3 million in 2024 and averaged -$7.5 million.
- Per our database at Business Quant, SAB Biotherapeutics' EBT tumbled by 78208.14% in 2023 and then skyrocketed by 5649.72% in 2024.
- SAB Biotherapeutics' EBT (Quarter) stood at -$11.6 million in 2021, then soared by 32.05% to -$7.8 million in 2022, then crashed by 191.21% to -$22.9 million in 2023, then skyrocketed by 56.5% to -$9.9 million in 2024, then decreased by 21.36% to -$12.1 million in 2025.
- Its last three reported values are -$12.1 million in Q3 2025, -$9.8 million for Q2 2025, and -$10.8 million during Q1 2025.